131 results
8-K
EX-10.1
64nn q6p89q
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
vo6hcidy
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.2
fgc8hqt6k vf4
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
v12hfn2cuq6ff4z8 xaa
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
q9kogcbpsjy1kqei5m
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
mqg 0nkdbju
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
5tmhycpy2
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
vw4af85j
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
crv19w3ede8iey
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
7213j7
30 May 23
Business combination disclosure
4:21pm
8-K
m24oe
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
io3qs82usylp97zro
22 May 23
Business combination disclosure
7:01am
8-K
jc7i3
22 May 23
Other Events
6:59am